• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

    9/9/25 5:30:00 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care
    Get the next $OSRH alert in real time by email

    BELLEVUE, Wash., Sept. 9, 2025 /PRNewswire/ -- OSR Holdings (NASDAQ:OSRH) today announced that on September 5, 2025, it received a written notification from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

    OSR Holdings logo (PRNewsfoto/OSR Holdings)

    The notice does not affect the listing of OSR Holdings' common stock, which will continue to trade on the Nasdaq Capital Market under the ticker symbol "OSRH." In accordance with Nasdaq rules, the Company has until March 4, 2026 to regain compliance.

    Despite recent share price volatility, OSR Holdings continues to believe that its market value does not reflect the strength of its business fundamentals or the momentum across its programs. The Company continues to:

    • Advance its portfolio of transformative programs in key therapeutic areas including oral immunotherapies and regenerative medicine.
    • Build its Digital Asset Treasury (DAT) strategy to reinforce financial flexibility and resilience.
    • Conduct due diligence on Woori IO, a developer of non-invasive glucose monitoring technology, underscoring a commitment to advancing high-impact, complementary innovations.

    While executing these strategic initiatives, the Company has also observed trading activities in its shares that appear inconsistent with underlying fundamentals. Publicly available SEC fails-to-deliver (FTD) data has reflected significantly elevated levels of settlement imbalances in OSRH on notable dates marked by high trading volatility, heavy volumes, or material press releases such as M&A term sheet announcements. The Company believes this data may indicate the presence of manipulative short selling practices that have contributed to downward pressure on its share price.

    "Our focus remains firmly on advancing our scientific programs and creating long-term value for our stakeholders," said Peter Hwang, Chief Executive Officer of OSR Holdings. "We take market integrity very seriously, and we will continue to pursue both operational execution and proactive measures to address unusual trading dynamics."

    OSR Holdings is committed to protecting the interests of all shareholders. The Company intends to actively monitor trading activity, engage with regulators as appropriate, and evaluate all available options to ensure a fair and orderly market for its securities.

    "OSR Holdings is built on strong scientific foundations, a diversified innovation pipeline, and forward-looking strategies such as our digital asset treasury initiatives," added Tim Smith, Head of Global Investor Relations. "We remain confident in the long-term value of our business, and while we are committed to addressing unusual trading dynamics, our priority is to continue advancing programs that can make a meaningful difference for patients and shareholders alike."

    About OSR Holdings

    OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit www.OSR‑Holdings.com.

    Contact

    Investor Relations

    OSR Holdings, Inc.

    Email: ir@osr‑holdings.com

    Forward-Looking Statements

    This press release contains forward-looking statements, including statements regarding the Company's ability to regain compliance with Nasdaq listing standards, its development pipeline, digital asset treasury strategy, and due diligence activities with Woori IO. These statements are subject to risks and uncertainties, and actual results may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-receives-nasdaq-minimum-bid-price-deficiency-notice-company-highlights-unusual-trading-activity-302551528.html

    SOURCE OSR Holdings

    Get the next $OSRH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSRH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSRH
    SEC Filings

    View All

    OSR Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    3/16/26 8:00:22 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    3/10/26 8:01:02 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    1/27/26 9:26:39 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream

    MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to

    3/31/26 7:00:00 AM ET
    $AEMD
    $ATCH
    $BESS
    Medical/Dental Instruments
    Health Care
    Finance: Consumer Services
    Finance

    Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials

    BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China. This announcement is being made in accordance with Regulation FD to ensure broad, non-exclusionary public dissemination of this information.

    3/19/26 9:44:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

    BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy. The FDA has clarified that consumer wearable products providing non-medical, wellness-oriented health insights—when appropriately labeled and marketed—generally fall outside the scope of m

    1/22/26 9:55:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Fierz Reto Kaspar

    3 - OSR Holdings, Inc. (0001840425) (Issuer)

    10/24/25 12:58:23 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Leadership Updates

    Live Leadership Updates

    View All

    Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

    BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens Vaximm's leadership with deep, long-standing expertise in the company's core technology. Dr. Wieckowski brings multidisciplinary experience spanning immunology and advanced data science, a profile uniquely poised to integrate reproducible analytical workflows and data-driven strategies to acc

    1/16/26 9:20:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

    BELLEVUE, Wash., Nov. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced the appointment of Dr. Andreas Niethammer, M.D., Ph.D., Vaximm AG's Chief Medical Offer and scientific co-founder, as Chief Executive Officer (CEO), effective December 1, 2025. Vaximm is a Swiss-German biotech company developing oral T-cell immunotherapies for cancer and a subsidiary of OSR Holdings, Inc. Dr. Niethammer, an internationally recognized oncology expert, co-founded Vaximm to translate his pioneering work at The Scripps Research Institute, where he first described the co

    11/14/25 11:10:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

    BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Dr. Niethammer is an internationally recognized oncology expert with over two decades

    7/15/25 7:30:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care